Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Converting Red Blood Cells to Efficient Microreactors for Blood Detoxification.

Xu C, Yang X, Fu X, Tian R, Jacobson O, Wang Z, Lu N, Liu Y, Fan W, Zhang F, Niu G, Hu S, Ali IU, Chen X.

Adv Mater. 2017 Feb;29(6). doi: 10.1002/adma.201603673. Epub 2016 Nov 28.

2.

Penetrating the Blood-Brain Barrier: Promise of Novel Nanoplatforms and Delivery Vehicles.

Ali IU, Chen X.

ACS Nano. 2015 Oct 27;9(10):9470-4. doi: 10.1021/acsnano.5b05341. Epub 2015 Sep 25.

3.

In vivo albumin labeling and lymphatic imaging.

Wang Y, Lang L, Huang P, Wang Z, Jacobson O, Kiesewetter DO, Ali IU, Teng G, Niu G, Chen X.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):208-13. doi: 10.1073/pnas.1414821112. Epub 2014 Dec 22.

4.

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.

Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2726-33. doi: 10.1158/1055-9965.EPI-09-0363. Epub 2009 Sep 15.

5.

Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.

Fatima N, Chelius D, Luke BT, Yi M, Zhang T, Stauffer S, Stephens R, Lynch P, Miller K, Guszczynski T, Boring D, Greenwald P, Ali IU.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):41-9.

6.

Protective effect of Cox-2 allelic variants on risk of colorectal adenoma development in African Americans.

Ashktorab H, Tsang S, Luke B, Sun Z, Adam-Campbell L, Kwagyan J, Poirier R, Akter S, Akhgar A, Smoot D, Munroe DJ, Ali IU.

Anticancer Res. 2008 Sep-Oct;28(5B):3119-23.

7.

Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib.

Fatima N, Yi M, Ajaz S, Stephens RM, Stauffer S, Greenwald P, Munroe DJ, Ali IU.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3051-61. doi: 10.1158/1055-9965.EPI-08-0261. Epub 2008 Oct 28.

8.

MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.

Levine AJ, Wallace K, Tsang S, Haile RW, Saibil F, Ahnen D, Cole BF, Barry EL, Munroe DJ, Ali IU, Ueland P, Baron JA.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2409-15. doi: 10.1158/1055-9965.EPI-07-2670.

9.

Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.

Lou J, Fatima N, Xiao Z, Stauffer S, Smythers G, Greenwald P, Ali IU.

Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1598-606.

10.

Plasma proteomic profiling: search for lung cancer diagnostic and early detection markers.

Ali IU, Xiao Z, Malone W, Smith M, Conrads TP, Veenstra TD, Greenwald P, Luke BT, McLarty JW.

Oncol Rep. 2006 May;15(5):1367-72.

PMID:
16596212
11.
12.

Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.

Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RK, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU.

Cancer Res. 2004 Apr 15;64(8):2904-9.

13.

Effect of a 4-month tea intervention on oxidative DNA damage among heavy smokers: role of glutathione S-transferase genotypes.

Hakim IA, Harris RB, Chow HH, Dean M, Brown S, Ali IU.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):242-9.

14.

Molecular profiling of angiogenesis markers.

Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR.

Am J Pathol. 2002 Jul;161(1):35-41.

15.

Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials.

Ali IU, Senger DR, Smith LE.

Urology. 2001 Apr;57(4 Suppl 1):143-7. Review.

PMID:
11295614
16.

Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.

Herbert BS, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, Shay JW.

J Natl Cancer Inst. 2001 Jan 3;93(1):39-45.

PMID:
11136840
17.

Gatekeeper for endometrium: the PTEN tumor suppressor gene.

Ali IU.

J Natl Cancer Inst. 2000 Jun 7;92(11):861-3. No abstract available.

PMID:
10841815
18.

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.

Ali IU, Schriml LM, Dean M.

J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32. Review.

PMID:
10564676
19.
20.

Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.

Saxena A, Robertson JT, Ali IU.

Oncogene. 1996 Aug 1;13(3):661-4.

PMID:
8760309
21.

Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene.

Karl M, Von Wichert G, Kempter E, Katz DA, Reincke M, Mönig H, Ali IU, Stratakis CA, Oldfield EH, Chrousos GP, Schulte HM.

J Clin Endocrinol Metab. 1996 Jan;81(1):124-9.

PMID:
8550738
22.

Heterogeneity of subcellular localization of p53 protein in human glioblastomas.

Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, Oldfield EH.

Cancer Res. 1994 Jan 1;54(1):1-5.

23.

Close proximity of c-erbA2 and c-erbA-beta genes on the short arm of chromosome 3.

Ali IU, Saxena A, Meissner S, Barrick J, Lidereau R.

Oncogene. 1993 Aug;8(8):2299-301.

PMID:
8393165
24.

Structure of the POMC promoter region in pituitary and extrapituitary ACTH producing tumors.

Mönig H, Ali IU, Oldfield EH, Schulte HM.

Exp Clin Endocrinol. 1993;101(1):36-8.

PMID:
8386673
25.

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH.

J Clin Invest. 1993 Jan;91(1):153-9.

26.

Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.

Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH, Ali IU.

Cancer Res. 1992 Dec 1;52(23):6716-21. Erratum in: Cancer Res 1993 Mar 15;53(6):1472.

27.

Clonal composition of glioblastoma multiforme.

Berkman RA, Clark WC, Saxena A, Robertson JT, Oldfield EH, Ali IU.

J Neurosurg. 1992 Sep;77(3):432-7.

PMID:
1324297
28.

Aberrant splicing of Gs alpha transcript in transformed human astroglial and glioblastoma cell lines.

Ali IU, Reinhold W, Salvador C, Aguanno S.

Nucleic Acids Res. 1992 Aug 25;20(16):4263-7.

29.

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.

Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU.

Cancer Res. 1992 Aug 15;52(16):4550-3.

30.
31.

Clonal composition of pituitary adenomas in patients with Cushing's disease: determination by X-chromosome inactivation analysis.

Schulte HM, Oldfield EH, Allolio B, Katz DA, Berkman RA, Ali IU.

J Clin Endocrinol Metab. 1991 Dec;73(6):1302-8.

PMID:
1720126
33.
34.

Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma.

Ali IU, Campbell G, Lidereau R, Callahan R.

Oncogene Res. 1988 Sep;3(2):139-46.

PMID:
3226722
36.

Amplification of the int-2 gene in primary human breast tumors.

Lidereau R, Callahan R, Dickson C, Peters G, Escot C, Ali IU.

Oncogene Res. 1988 Feb;2(3):285-91.

PMID:
2835739
37.

Heterogeneity of genetic alterations in primary human breast tumors.

Ali IU, Lidereau R, Callahan R.

Cancer Treat Res. 1988;40:25-48. Review. No abstract available.

PMID:
2908654
38.

Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia.

Ali IU, Lidereau R, Theillet C, Callahan R.

Science. 1987 Oct 9;238(4824):185-8.

PMID:
3659909
39.

Human normal and tumor cell lines: comparison of fibronectins and collagens.

Ali IU, Rasheed S.

Cancer Invest. 1987;5(1):17-24.

PMID:
3580944
40.
41.

Analysis of phosphorylation sites on fibronectin.

Ali IU.

FEBS Lett. 1984 Oct 15;176(1):169-75. No abstract available.

42.
43.
44.

Structural comparison of fibronectins from normal and transformed cells.

Ali IU, Hunter T.

J Biol Chem. 1981 Jul 25;256(14):7671-7.

45.

A large glycoprotein lost from the surfaces of transformed cells.

Hynes RO, Ali IU, Destree AT, Mautner V, Perkins ME, Senger DR, Wagner DD, Smith KK.

Ann N Y Acad Sci. 1978 Jun 20;312:317-42. Review. No abstract available.

PMID:
386882
46.
47.

Effects of LETS glycoprotein on cell motility.

Ali IU, Hynes RO.

Cell. 1978 Jun;14(2):439-46.

PMID:
667950
48.

LETS glycoprotein: arrangement and function at the cell surface.

Hynes RO, Ali IU, Mautner VM, Destree A.

Birth Defects Orig Artic Ser. 1978;14(2):139-53. Review.

PMID:
346077
49.

Effects of cytochalasin B and colchicine on attachment of a major surface protein of fibroblasts.

Ali IU, Hynes RO.

Biochim Biophys Acta. 1977 Nov 15;471(1):16-24.

PMID:
921971

Supplemental Content

Support Center